Mersana Therapeutics to Host Virtual Analyst and Investor Event
Debra L. Richardson , MD, Associate Professor and Section Chief,Division of Gynecologic Oncology at theOU Health Stephenson Cancer Center and theSarah Cannon Research Institute , will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company’s first-in-class ADC candidate targeting NaPi2b.- Mersana’s management team will detail the Company’s plans for the registration-enabling study of XMT-1536 in platinum-resistant ovarian cancer and outline its objectives for longer-term life cycle management studies to evaluate the potential of XMT-1536 in platinum-sensitive ovarian cancer.
- Mersana’s management team will disclose preclinical data supporting the development of the Company’s first-in-class B7-H4 DolaLock ADC development candidate.
- Mersana’s management team will outline the Company’s anticipated 2021 goals and milestones for its clinical and early-stage ADC programs.
Webcast and Conference Call Details
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at https://ir.mersana.com/events-and-presentations. Analyst and Investors may ask a question during the live Q&A by dialing (855) 940-5308 (toll-free domestic) or (929) 517-9745 (international) and providing the Conference ID 6265117.
About Mersana Therapeutics
Contact:
Investor & Media Contact
617-844-8577
scarmody@mersana.com
Source: Mersana Therapeutics, Inc.